Super Bowl ad for copycat weight loss drugs stokes pharma power debate
As the Philadelphia Eagles romped to victory against the Kansas City Chiefs in the Super Bowl LIX, the eyes of…
Metabolic Disorders
-
-
Novo Nordisk plans new study for CagriSema, targets 2026 submission
Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential…
-
Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks associated with chronic…
-
GLP-1RA developer Metsera targets $289m IPO
US-based Metsera has set its sights on a $289m public listing as the weight loss drug developer becomes one of…
-
Can-Fite BioPharma secures US patent for Namodenoson
Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment. Set…
-
JP Morgan 2025: reduced dosing and expanded manufacturing paving way for Amgen’s obesity entrance
Amgen has reported that its once-monthly dosing regimen and manufacturing capabilities will be key to entering the obesity market. Presenting…
-
FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluation
The US Food and Drug Administration (FDA) has stood by an earlier decision confirming that the tirzepatide shortage is over.…
-
MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset
Merck & Co (MSD) has entered an exclusive global licence agreement with China-based Hansoh Pharma for a preclinical oral small…
-
FDA targets more online vendors selling unapproved GLP-1RA products
The US Food and Drug Administration (FDA) has issued warning letters to four companies selling unapproved glucagon-like peptide-1 receptor agonist…
-
Egyptian Drug Authority approves Lilly and EVA’s insulin injection
Eli Lilly and EVA Pharma have announced approval from the Egyptian Drug Authority for the human insulin glargine injection to…
